Loading quotes...
Forecast
The analysts' average price target is €36.46 (+2.79%). The median is €36.46 (+2.79%).
| Buy |
8 |
| Hold |
6 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Centessa announces CEO change; shares fall after strategic realignment
Centessa reports that Mario Alberto Accardi will replace Saurabh Saha as CEO on January 1, 2026, and join the board; Saha is stepping down and will remain as an adviser. The stock subsequently fell about 4%. The company is refocusing its strategy on the orexin/OX2R portfolio: lead candidate ORX750 is expected to enter an approval-relevant program for narcolepsy and idiopathic hypersomnia in the first quarter of 2026, and other OX2R candidates such as ORX142 and ORX489 are expected to hit key milestones in 2026. » More on de.investing.com
Centessa Pharmaceuticals hits 52-week high at $25.44
The ADRs of Centessa Pharmaceuticals rose to a 52-week high of $25.44 after the stock gained 32.59% over the past year and 71.41% in six months; the current price is about 166% above the annual low of $9.60. Analyst price targets range from $27 to $49, while InvestingPro flags a possible overvaluation versus fair value. Centessa announced a public offering of 11.6 million ADS at $21.50 (gross proceeds ~ $250 million, fully underwritten) and received a buy from Truist with a $30.00 target following preliminary phase-2a data on ORX750. » More on de.investing.com
Centessa announces public offering of ADS, shares fall in after-hours
Centessa's share fell about 2.5% in after-hours trading after the company announced a guaranteed public placement of American Depositary Shares (each representing one common share). All offered ADS will be sold by Centessa, and the underwriting banks have a 30-day option to purchase up to 15% of the shares. Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities are joint bookrunners; the offering is subject to market and other conditions and may lead to dilution for existing shareholders. » More on de.investing.com
Centessa Pharmaceuticals sets ADS offering price at $21.50
Centessa Pharmaceuticals sets the price for a public, syndicated offering of 11,627,907 American Depositary Shares (ADS) at $21.50 per ADS and expects gross proceeds of about $250 million before expenses. The transaction, in which all of Centessa’s ADSs will be sold, is expected to close around November 14, 2025, and includes a 30-day overallotment option for up to 1,744,186 ADS. Joint book-running managers are Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities; the ADSs are being offered on the basis of a Form S-3 filed in September 2024. » More on de.investing.com
Centessa Pharmaceuticals hits 52-week high at $25.35
Centessa Pharmaceuticals ADRs marked a new 52-week high at $25.35 and are up about 56.7% year to date. Market capitalization is roughly $3.34 billion; analyst price targets range from $27 to $40, with Stephens, Oppenheimer and Truist recently issuing buy recommendations or positive ratings. Key upcoming events include the quarterly report on November 17 and expected Phase‑2a data for ORX750 before year‑end. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | March 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -206.13k | - |
| Net profit | -68.46m | - |
| EBITDA | -65.16m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.71bn |
Number of shares | 154.73m |
52-week high/low | €36.97 - €11.65 |
Dividend yield | 94.36% |
Dividends TTM | €33.47 |
Beta | 1.12 |
P/E ratio | -22.75 |
PEG ratio | 3.15 |
P/B ratio | 12.76 |
P/S ratio | 0.00 |
Company profile
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
| Name | Centessa Pharmaceuticals ADR Aktie |
| CEO | Mario Alberto Accardi |
| Headquarters | Altrincham,
United Kingdom |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 28/05/2021 |
| Employees | 129 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | CNTA |
Frankfurt | 260.F |
Düsseldorf | 260.DU |
München | 260.MU |
London | 0ACX.L |